QualityMetric Collaborates with Drug Developers to Address Pain Points of Rare Diseases

We offer several patient-reported outcome (PRO) measurement solutions that can help document the etiology, progression, patient experience, symptoms and impact of rare diseases.


Vesey Street Capital Partners-Backed QualityMetric Adds Angela Host as Chief Commercial Officer

Ms. Host’s distinguished career spans 20+ years, with progressively larger leadership roles in healthcare across life sciences, provider, and payer markets.

Read More

Vesey Street Capital Partners-Backed QualityMetric Adds John Hart as Chief Financial Officer

Mr. Hart will join the team led by Chief Executive Officer Garth “Gus” Gardner, who has been in that role since soon after the VSCP-led recapitalization of the company in August of 2020.

Read More

QualityMetric Co-authors New Qualitative Study on hATTR

QualityMetric’s own Kimberly Raymond, Andrew Lovley, and Michelle White co-author a new study on the humanistic burden of hereditary transthyretin (hATTR) amyloidosis from the patient’s perspective.

Read More

QualityMetric Co-authors Study Supporting Content Validity of the ACT

QualityMetric’s Vice President and Senior Scientist, Mark Kosinski, co-authors a study for determining whether the content of the Asthma Control Test (ACT) serves as a valid measure of asthma control.

Read More

How We Identify the Best PRO Tools for Medical Device Manufacturers

Our experts provide medical device clients with leading strategic measurement services, qualitative and quantitative research and patient journey studies, PRO outcomes analyses, rare disease research, and PRO regulatory support services.

Read More

QualityMetric Develops PROs for Determining Worldwide Impact of COVID-19

As pharma, biotech, medical device companies and academic researchers race to discover treatments for COVID-19, they require measurement and outcomes reporting for capturing real-world evidence.

Read More

A Letter to Our Customers

We want to inform you of a recent development that will allow us to enhance the services and support we provide.

Read More

Vesey Street Capital Partners Announces Gus Gardner as Chief Executive Officer of QualityMetric

Gardner’s appointment comes as the company seeks to build on its position as the preeminent provider of Patient Reported Outcomes (PRO) and Clinical Outcome Assessments (COA) solutions and services to healthcare and life sciences companies.

Read More